3 completed, 3 terminated, 3 withdrawn, 1 active not recruiting. 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 3, Terminated 3, Withdrawn 3, Active not recruiting 1, Recruiting 1 |
Follow Chronic Inflammatory Demyelinating Polyneuropathy: new trials by email Literature Review of Chronic Inflammatory Demyelinating Polyneuropathy trials Research Report on Chronic Inflammatory Demyelinating Polyneuropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Batoclimab - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Immunovant Sciences GmbH | 26 | 2025-08-28 | 2026-08-11 |
| Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy Rituximab - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Withdrawn | University of Kansas Medical Center | 2025-07-01 | 2025-09-17 | |
| Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP NVG-2089 - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Nuvig Therapeutics, Inc. | 14 | 2025-04-25 | 2026-10-06 |
| Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Imeroprubart, Placebo - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Recruiting | Immunovant Sciences GmbH | 162 | 2025-03-18 | 2026-09-30 |
| To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly, Placebo - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Terminated | Immunovant Sciences GmbH | 94 | 2022-12-15 | 2026-08-11 |
| SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study MD1003 - Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy | Phase 2 | Completed | MedDay Pharmaceuticals SA | 15 | 2016-12-05 | 2020-11-02 |
| Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy H.P. Acthar® Gel - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Withdrawn | Mamatha Pasnoor, MD | 2015-08-01 | 2016-07-18 | |
| Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy lipoic acid - CIDP, Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Completed | Oregon Health and Science University | 7 | 2009-02-01 | 2020-08-19 |
| Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine - Autoimmune Disease, Neurologic Autoimmune Disease | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2008-06-01 | 2026-02-27 |
| Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy hematopoietic stem cell transplantation - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Completed | Northwestern University | 80 | 2005-02-21 | 2020-07-23 |
| High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Cyclophosphamide - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Withdrawn | Stony Brook University | 2003-10-01 | 2021-11-09 |
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (11) · Autoimmune Diseases (3) · Autoimmune Diseases of the Nervous System (1) · Charcot-Marie-Tooth Disease (1) · Lambert-Eaton Myasthenic Syndrome (1) · Myasthenia Gravis (1) · Neuromyelitis Optica (1) · Opsoclonus-Myoclonus Syndrome (1) · Peripheral Nervous System Diseases (1) · Rasmussen subacute encephalitis (1) · Stiff-Person Syndrome (1) · Vasculitis, Central Nervous System (1)
Chronic Disease (11) · Demyelinating Diseases (11) · Disease Attributes (11) · Immune System Diseases (11) · Nervous System Diseases (11) · Neuromuscular Diseases (11) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Polyneuropathies (11) · Polyradiculoneuropathy (11) · Autoimmune Diseases of the Nervous System (10) · Peripheral Nervous System Diseases (10) · Autoimmune Diseases (8) · Neurodegenerative Diseases (2) · Brain Diseases (1)
Antilymphocyte Serum (1) · Biotin (1) · Carmustine (1) · Cyclophosphamide (1) · Cytarabine (1) · Etoposide (1) · Hematopoietic Stem Cell Transplantation (1) · Injections, Subcutaneous (1) · Melphalan (1) · Peripheral Blood Stem Cell Transplantation (1) · Prednisone (1) · Rituximab (1) · Thioctic Acid (1) · carmustine, poliferprosan 20 drug combination (1) · deltacortene (1)
Immunovant Sciences GmbH (3) · Fred Hutchinson Cancer Center (1) · Mamatha Pasnoor, MD (1) · MedDay Pharmaceuticals SA (1) · Northwestern University (1) · Nuvig Therapeutics, Inc. (1) · Oregon Health and Science University (1) · Stony Brook University (1) · University of Kansas Medical Center (1)
United States (8) · Argentina (3) · Belgium (3) · Brazil (3) · Germany (3) · Greece (3) · Italy (3) · Poland (3) · Romania (3) · Serbia (3) · Slovakia (3) · Bulgaria (2) · Denmark (2) · Finland (2) · Norway (2)
Frederic Sedel, MD (1) · Jau-Shin Lou, MD, PhD (1) · Leona Holmberg (1) · Mamatha Pasnoor, MD (1) · Mazen Dimachkie, MD (1) · Richard Burt, MD (1)